IBI3038
/ Innovent Biologics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 06, 2026
Preclinical characterization of IBI3038, an anti-IGF-1R and anti-IL6 bispecific antibody that potently inhibits skin fibrosis
(EADV 2026)
- "Conclusions An innovative and First-in-class IGF-1RxIL-6 bispecific antibody is characterized for its potent and synergistic inhibition on inflammation and fibrosis development. IBI3038 can potentially bring new treatment and clinical benefits to patients of fibrosis-related disease, as systemic sclerosis."
Bispecific • Preclinical • Fibrosis • Immunology • Inflammation • Scleroderma • Systemic Sclerosis • IGF1 • IL6R
1 to 1
Of
1
Go to page
1